

Jae Yong Cho

List of Publications by Citations

Source: <https://exaly.com/author-pdf/2838562/jae-yong-cho-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

60
papers

4,720
citations

27
h-index

61
g-index

61
ext. papers

5,771
ext. citations

6.3
avg, IF

4.87
L-index

#	Paper	IF	Citations
60	Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet, The</i> , 2017 , 390, 2461-2471	40	1123
59	Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. <i>Lancet, The</i> , 2012 , 379, 315-21	40	1085
58	Gene expression signature-based prognostic risk score in gastric cancer. <i>Clinical Cancer Research</i> , 2011 , 17, 1850-7	12.9	232
57	Clinical Significance of Four Molecular Subtypes of Gastric Cancer Identified by The Cancer Genome Atlas Project. <i>Clinical Cancer Research</i> , 2017 , 23, 4441-4449	12.9	213
56	Randomized, Double-Blind Phase II Trial With Prospective Classification by ATM Protein Level to Evaluate the Efficacy and Tolerability of Olaparib Plus Paclitaxel in Patients With Recurrent or Metastatic Gastric Cancer. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3858-65	2.2	202
55	Addition of docetaxel to S-1 without platinum prolongs survival of patients with advanced gastric cancer: a randomized study (START). <i>Journal of Cancer Research and Clinical Oncology</i> , 2014 , 140, 319-28	4.9	132
54	Clinical and genomic landscape of gastric cancer with a mesenchymal phenotype. <i>Nature Communications</i> , 2018 , 9, 1777	17.4	116
53	Prognostic biomarkers for esophageal adenocarcinoma identified by analysis of tumor transcriptome. <i>PLoS ONE</i> , 2010 , 5, e15074	3.7	106
52	Efficacy of Sequential Ipilimumab Monotherapy versus Best Supportive Care for Unresectable Locally Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer. <i>Clinical Cancer Research</i> , 2017 , 23, 5671-5678	12.9	91
51	Capecitabine combined with gemcitabine (CapGem) as first-line treatment in patients with advanced/metastatic biliary tract carcinoma. <i>Cancer</i> , 2005 , 104, 2753-8	6.4	86
50	Clinicopathologic implications of the BRAF(V600E) mutation in papillary thyroid cancer: a subgroup analysis of 3130 cases in a single center. <i>Thyroid</i> , 2013 , 23, 1423-30	6.2	83
49	Gene expression signature analysis identifies vorinostat as a candidate therapy for gastric cancer. <i>PLoS ONE</i> , 2011 , 6, e24662	3.7	83
48	AMPK γ modulation in cancer progression: multilayer integrative analysis of the whole transcriptome in Asian gastric cancer. <i>Cancer Research</i> , 2012 , 72, 2512-21	10.1	82
47	A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data. <i>Gastric Cancer</i> , 2020 , 23, 510-519	7.6	72
46	Comparison of two inflammation-based prognostic scores in patients with unresectable advanced gastric cancer. <i>Oncology</i> , 2012 , 83, 292-9	3.6	66
45	Evaluation of E1B gene-attenuated replicating adenoviruses for cancer gene therapy. <i>Cancer Gene Therapy</i> , 2002 , 9, 725-36	5.4	66
44	Overexpression of the M2 isoform of pyruvate kinase is an adverse prognostic factor for signet ring cell gastric cancer. <i>World Journal of Gastroenterology</i> , 2012 , 18, 4037-43	5.6	62

43	Ramucirumab as Second-Line Treatment in Patients With Advanced Hepatocellular Carcinoma: Analysis of REACH Trial Results by Child-Pugh Score. <i>JAMA Oncology</i> , 2017 , 3, 235-243	13.4	59
42	Overexpression of miR-196b and HOXA10 characterize a poor-prognosis gastric cancer subtype. <i>World Journal of Gastroenterology</i> , 2013 , 19, 7078-88	5.6	54
41	Molecular diagnosis for personalized target therapy in gastric cancer. <i>Journal of Gastric Cancer</i> , 2013 , 13, 129-35	3.2	49
40	Treatment outcome of patients with anaplastic thyroid cancer: a single center experience. <i>Yonsei Medical Journal</i> , 2012 , 53, 352-7	3	46
39	Thioredoxin and thioredoxin-interacting protein as prognostic markers for gastric cancer recurrence. <i>World Journal of Gastroenterology</i> , 2012 , 18, 5581-8	5.6	39
38	Prognostic Factor Analysis of Overall Survival in Gastric Cancer from Two Phase III Studies of Second-line Ramucirumab (REGARD and RAINBOW) Using Pooled Patient Data. <i>Journal of Gastric Cancer</i> , 2017 , 17, 132-144	3.2	36
37	Comparison of Surgery Plus Chemotherapy and Palliative Chemotherapy Alone for Advanced Gastric Cancer with Krukenberg Tumor. <i>Cancer Research and Treatment</i> , 2015 , 47, 697-705	5.2	32
36	Subgroup analysis of East Asians in RAINBOW: A phase 3 trial of ramucirumab plus paclitaxel for advanced gastric cancer. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016 , 31, 581-9	4	31
35	Antifibrotic effects of magnesium lithospermate B on hepatic stellate cells and thioacetamide-induced cirrhotic rats. <i>Experimental and Molecular Medicine</i> , 2011 , 43, 341-9	12.8	30
34	Clinical trial of nintedanib in patients with recurrent or metastatic salivary gland cancer of the head and neck: A multicenter phase 2 study (Korean Cancer Study Group HN14-01). <i>Cancer</i> , 2017 , 123, 1958-1964	6.4	28
33	Non-Hodgkin's lymphoma of the sphenoid sinus presenting as isolated oculomotor nerve palsy. <i>World Journal of Surgical Oncology</i> , 2007 , 5, 86	3.4	27
32	Overexpression of c-ErbB-2 protein in gastric cancer by immunohistochemical stain. <i>Oncology</i> , 1996 , 53, 192-7	3.6	27
31	Overexpression of Endoplasmic Reticulum Oxidoreductin 1- α (ERO1L) Is Associated with Poor Prognosis of Gastric Cancer. <i>Cancer Research and Treatment</i> , 2016 , 48, 1196-1209	5.2	27
30	Phase II trial of dacomitinib in patients with HER2-positive gastric cancer. <i>Gastric Cancer</i> , 2016 , 19, 1095-1103	11.03	26
29	Outcome of adjuvant therapy for gallbladder cancer. <i>Oncology</i> , 2010 , 79, 168-73	3.6	26
28	Exploratory subgroup analysis of patients with prior trastuzumab use in the ATTRACTION-2 trial: a randomized phase III clinical trial investigating the efficacy and safety of nivolumab in patients with advanced gastric/gastroesophageal junction cancer. <i>Gastric Cancer</i> , 2020 , 23, 143-153	7.6	26
27	Erlotinib monotherapy for stage IIIB/IV non-small cell lung cancer: a multicenter trial by the Korean Cancer Study Group. <i>Journal of Thoracic Oncology</i> , 2009 , 4, 1136-43	8.9	23
26	A phase I/II study of poziotinib combined with paclitaxel and trastuzumab in patients with HER2-positive advanced gastric cancer. <i>Gastric Cancer</i> , 2019 , 22, 1206-1214	7.6	17

25	Relationship between p53 overexpression and gastric cancer progression. <i>Oncology</i> , 1997 , 54, 166-70	3.6	17
24	Docetaxel-induced onycholysis: the role of subungual hemorrhage and suppuration. <i>Yonsei Medical Journal</i> , 2007 , 48, 124-6	3	17
23	Development and Validation of a Six-Gene Recurrence Risk Score Assay for Gastric Cancer. <i>Clinical Cancer Research</i> , 2016 , 22, 6228-6235	12.9	17
22	Efficacy and tolerability of ramucirumab monotherapy or in combination with paclitaxel in gastric cancer patients from the Expanded Access Program Cohort by the Korean Cancer Study Group (KCSG). <i>Gastric Cancer</i> , 2018 , 21, 819-830	7.6	15
21	Gemcitabine and oxaliplatin combination as first-line treatment for advanced pancreatic cancer: a multicenter phase II study. <i>Cancer Chemotherapy and Pharmacology</i> , 2009 , 64, 317-25	3.5	15
20	Targeted therapy in gastric cancer: personalizing cancer treatment based on patient genome. <i>World Journal of Gastroenterology</i> , 2014 , 20, 2042-50	5.6	15
19	Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab. <i>Gastric Cancer</i> , 2021 , 24, 946-958	7.6	13
18	A phase II study of capecitabine plus gemcitabine in patients with locally advanced or metastatic pancreatic cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2008 , 62, 763-8	3.5	12
17	Prognostic factors of second and third line chemotherapy using 5-fu with platinum, irinotecan, and taxane for advanced gastric cancer. <i>Cancer Research and Treatment</i> , 2011 , 43, 236-43	5.2	12
16	Phase II trial of oxaliplatin combined with leucovorin and fluorouracil for recurrent/metastatic biliary tract carcinoma. <i>Anti-Cancer Drugs</i> , 2008 , 19, 631-5	2.4	10
15	Comparison of capecitabine and oxaliplatin with S-1 as adjuvant chemotherapy in stage III gastric cancer after D2 gastrectomy. <i>PLoS ONE</i> , 2017 , 12, e0186362	3.7	10
14	Retrospective comparison of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (modified FAM) combination chemotherapy versus palliative therapy in treatment of advanced gastric cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1997 , 20, 484-9	2.7	10
13	9-cis retinoic acid induces insulin-like growth factor binding protein-3 through DR-8 retinoic acid responsive elements. <i>Cancer Biology and Therapy</i> , 2006 , 5, 586-92	4.6	9
12	Survival analysis based on human epidermal growth factor 2 status in stage II-III gastric cancer. <i>World Journal of Gastroenterology</i> , 2017 , 23, 7407-7414	5.6	9
11	Efficacy of adjuvant chemotherapy for completely resected stage IB non-small cell lung cancer: a retrospective study. <i>Journal of Thoracic Disease</i> , 2018 , 10, 2279-2287	2.6	9
10	Oxaliplatin combined with continuous infusion of 5-fluorouracil as first-line chemotherapy in patients with metastatic or recurrent gastric adenocarcinoma. <i>Chemotherapy</i> , 2009 , 55, 200-6	3.2	6
9	Salvage chemotherapy with docetaxel and epirubicin for advanced/metastatic gastric cancer. <i>Oncology</i> , 2007 , 73, 2-8	3.6	6
8	Gemcitabine Combined with Capecitabine Compared to Gemcitabine with or without Erlotinib as First-Line Chemotherapy in Patients with Advanced Pancreatic Cancer. <i>Cancer Research and Treatment</i> , 2015 , 47, 266-73	5.2	6

7	Subgroup analysis of East Asian patients in REGARD: A phase III trial of ramucirumab and best supportive care for advanced gastric cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2018 , 14, 204-209	1.9	5
6	Impact of the Double Mutants on Spike Protein of SARS-CoV-2 B.1.617 Lineage on the Human ACE2 Receptor Binding: A Structural Insight. <i>Viruses</i> , 2021 , 13,	6.2	3
5	Detection of fusion in cell-free DNA of a patient with advanced gastric cancer: A case report. <i>World Journal of Clinical Cases</i> , 2021 , 9, 2884-2889	1.6	1
4	Application of CRISPR/Cas9-based mutant enrichment technique to improve the clinical sensitivity of plasma EGFR testing in patients with non-small cell lung cancer.. <i>Cancer Cell International</i> , 2022 , 22, 82	6.4	0
3	Treatment of a Patient with Kaposi's Sarcoma Arising during Hemodialysis with the Multikinase Inhibitor Pazopanib. <i>Korean Journal of Medicine</i> , 2015 , 89, 113	0.5	
2	A Case of Adenocarcinoma Arising within Intra-Abdominal Bronchogenic Cyst. <i>Korean Journal of Medicine</i> , 2012 , 82, 374	0.5	
1	A Case of Adenocarcinomatous Transformation of a Sacrococcygeal Teratoma in an Adult. <i>Korean Journal of Medicine</i> , 2013 , 85, 101	0.5	